The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn MoreAs Seen in israel21c.org
About 200 million people worldwide suffer from age-related macular degeneration (AMD), and that number is expected to increase to nearly 300 million by 2040.
AMD is an eye disease that can blur central vision. It is the leading causes of blindness in Western countries, where people live long enough to experience such “first world” ocular issues. One in eight Westerners over the age of 60 can expect to develop AMD.
Already in 2021, the market for AMD treatment was estimated at $7.4 billion. The United States made up 52% of that market, the European Union 41% and Japan just over 7%.
Orsight Pharma Co-founder and CTO Marianna Truman is a Technion alumna.